Alina Baum is a prominent inventor based in Pleasantville, NY (US), known for her significant contributions to the field of biotechnology. With a total of eight patents to her name, she has made remarkable strides in developing antibodies that target viral infections, particularly those caused by coronaviruses.

Latest Patents

Among her latest patents are the "Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments." This patent provides antibodies and antigen-binding fragments that specifically bind to a coronavirus spike protein, offering methods for treating or preventing viral infections, including those caused by coronaviruses. Another notable patent is the "Anti-TMPRSS2 antibodies and antigen-binding fragments," which details antibodies that bind specifically to TMPRSS2, with applications in treating or preventing viral infections such as coronavirus and influenza.

Career Highlights

Alina Baum is currently employed at Regeneron Pharmaceuticals, Inc., where she continues to advance her research and development efforts in antibody therapies. Her work has been instrumental in addressing urgent health challenges posed by viral infections.

Collaborations

Alina collaborates with esteemed colleagues, including Christos Kyratsous and Robert Babb, who contribute to her innovative projects and research initiatives.

Conclusion

Alina Baum's contributions to antibody development are paving the way for new treatments against viral infections. Her dedication to innovation in biotechnology is evident through her patents and ongoing work at Regeneron Pharmaceuticals, Inc.

This text is generated by artificial intelligence and may not be accurate.